Wed, Dec 17, 2014, 11:42 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • news_to_use news_to_use Jul 1, 2013 3:46 AM Flag

    Don't Forget - Eisai and Pfizer had marketing Partnership-ARNA will jump 40% if reannounced

    Here is announcement from 2011 when they disolved due to patent expiration: "March 7, 2011 · 9:53 am
    Eisai cuts jobs and winds down Pfizer partnership
    Eisai has announced is winding down a co-promotion deal with Pfizer. Eisai has had a co-marketing agreement with Pfizer on Alzheimer’s disease treatment Aricept (donepezil) since 1994. The collaboration is set to expire in Japan at the end of 2012. Aricept’s US patent expired in November and cheaper generic copies of the drug are coming on the market undermining the rationale for the alliance"
    This would give PFE a chance to market Belviq & increase their revenue stream (badly needed after Lipitor going generic) with absolutely no risk. I doubt Eisai would lose any revenue because PFE's huge sales force would double the sales overnight. The stock price of ARNA should jump 40% or more on the announcement.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ARNA
3.90+0.120(+3.17%)Dec 17 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.